Liquidia Corporation saw a boost in its stock value following significant developments concerning its inhaled treprostinil product, YUTREPIA. The timeline for the FDA's exclusivity on a competing product, Tyvaso DPI®, is set to end on May 23, 2025, opening the door for YUTREPIA's final approval shortly after, according to GlobeNewswire. This anticipated clearance adds momentum to Liquidia's market position.
In a noteworthy legal advancement, a district court dismissed a cross-claim from United Therapeutics that challenged an amendment related to YUTREPIA. This decision effectively removes a critical legal obstacle and paves the way for further progress. TipRanks also highlighted this victory, which complements the FDA timeline to boost confidence in YUTREPIA's approval pathway.
Liquidia is not only making strides in regulatory and legal arenas but also fortifying its finances. The company amended its financial agreement with HealthCare Royalty Partners, securing up to $100 million to support YUTREPIA's launch. Analysts, as reported by TipRanks, have maintained a 'Buy' rating, reflecting a strong belief in the company's future prospects, with a price target set at $35.00 for its stock.